GVR Report cover Cancer Gene Therapy Market Size, Share & Trends Report

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-user (Research institutes, Biopharma companies), By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453196
  • Number of Pages: 0
  • Format: Electronic (PDF)

Cancer gene therapy has gained popularity in the last few years due to its high success rates during clinical and preclinical trials. The emerging field delivers a number of potential applications for cancer treatments. It offers various advances in the field of molecular biology, molecular genetics, immunology, virology, and molecular genetics. In various instances, this technique for cancer has been intended to augment existing therapies, such as immunotherapies and chemotherapies.

The cancer gene therapy approaches include oncolytic virotherapy, immunotherapy, and gene transfer. It can be utilized in different ways. For instance, altering gene regulation, replacing defective and missing genes with healthy genes, and introducing foreign genes into cells to change their function. The most common method is to replace a cancer-causing mutant gene with a healthy one.

Viral and non-viral vector products are needed for this technique. Non-viral vectors are normally utilized to transfer the different types of nucleic acids such as large DNA molecules ((Plasmid DNA: p DNA), small DNA, and RNA (m RNA, Si RNA, Ribozymes). Moreover, viral-vector therapies use modified viruses as drug-delivery vehicles to insert specific DNA sequences- regulatory RNAs (e.g. siRNAs), encoding genes, or other therapeutic substrates into cells.

Despite the slow clinical progress, researchers are undertaking efforts to develop specific non-toxic cancer therapies that are rising exponentially. As of now, more than 500 products under trial have been listed with the FDA. There is a number of strategies currently being followed during the cancer treatments. For instance,

  • Minimize cancerous cell proliferation and rise cell cycle control by restoring functions such as RB and p53

  • Rise in immunological rejection of tumor by the host

The pipeline for cancer therapies is quite strong and various companies are engaged in developing efficient products. Small biopharma companies are also emerging in the cell and gene therapy industry. For instance, Autolus Therapeutics is developing AAV-based gene therapies. The company is targeting patients suffering from chronic, systemic diseases using this technique.

Moreover, improving the regulatory scenario is also expected to increase the product launch in the market. For instance, in March 2021, Bluebird Bio and Bristol Myers Squibb received FDA approval for Abecma (idecabtagene vicleucel). It is a cell-based gene therapy to treat patients with multiple myeloma.

In addition, in February 2022, the University of Pennsylvania doctors’ team announced that cancer patients treated with gene therapy in 2010 shows no sign of cancer in the body. The two examples demonstrate how the therapy, known as CAR-T cell therapy, can fight cancer right away inside the body, and evolve to battle against the tumor. Moreover, in July 2022, ImmunoACT, backed by Laurus Labs, announced that it tested a novel gene therapy cure for leukemia and lymphoma. The lab is working with CD19 CAR-T Cell for leukemia and lymphoma. According to the lab, findings begin to appear after about a week.

Cancer Gene Therapy Market Segmentation

Segments

Details

By Therapy

  • Oncolytic Virotherapy
  • Gene-induced Immunotherapy
  • Gene Transfer

By End-user

  • Research Institutes
  • Biopharma Companies
  • Diagnostic Centres
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Major companies operating in the market include Abeona Therapeutics, Asklepios BioPharmaceutical, Celgene, Elevate Bio, GlaxoSmithKline, Bluebird bio, Genelux Corporation, OncoGenex Pharmaceuticals, Introgen Therapeutics, Altor Bioscience, Merck, GenVec, and BioCancell.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.